| Autor: |
Ayumi, TATEKOSHI, Tsutomu, SATO, Satoshi, IYAMA, Kohichi, TAKADA1, Kazuyuki, MURASE, Masahiro, YOSHIDA, Soushi, IBATA, Akari, HASHIMOTO, Yusuke, KAMIHARA, Hiroto, HORIGUCHI, Koji, MIYANISHI, Masayoshi, KOBUNE, Junji, KATO |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
札幌医学雑誌 = The Sapporo Medical Journal = The Sapporo medical journal. 87(1-6):35-47 |
| ISSN: |
0036-472X |
| Popis: |
Background: Malignant lymphoma patients have a high risk of bone mineral density (BMD) loss caused by corticosteroid-containing chemotherapy. Bisphosphonates have been used to prevent bone loss: however, little is known about effects of denosumab, a fully humanized monoclonal antibody inhibiting osteoclast-mediated bone resorption. Methods: This clinical trial was conducted in newly diagnosed lymphoma patients undergoing corticosteroid-containing chemotherapy. BMD was evaluated at baseline, and patients with a lumbar spine T-score of ? -1 were subcutaneously administered once with 60 mg of denosumab (“Denosumab” group). Patients with a T-score > -1 were allocated to the “No treatment” group. BMD was reevaluated at 24 weeks after enrollment. Bone turnover markers (BTMs) were collected at 0, 2, and 24 weeks.Results: Forty-three patients were enrolled (19 in the “Denosumab” group and 24 in the “No treatment” group). Patients in the “No treatment” group had decreased T-scores for the lumbar spine or femoral neck (P < 0.0001 or P = 0.0029, respectively) at 24 weeks after enrollment, whereas both T-scores were stable in the “Denosumab” group. Of the 18 patients in the “Denosumab” group, 12 had a T-score change from baseline (ΔT-score) of ? 0, whereas the remaining six patients had a ΔT-score < 0. These six patients had severely low T-scores at enrollment. Osteoclastic BTMs were strongly suppressed during the 24 weeks in the “Denosumab” group. The probability of major osteoporotic fracture or hip fracture in the “No treatment” group increased during the 24 weeks (P = 0.0195 or P = 0.0289, respectively), whereas pretreatment with denosumab prevented increased risks of both types of fractures. Conclusions: Our data suggests that BMD screening at diagnosis of lymphoma should be considered so that the bone health of lymphoma survivors can be improved with denosumab. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
